Marc Beer Joins LumeN XT And Is Greeted With Open Arms By The Company’s CEO Paul Rhyne

Marc Beer is a business leader who recently became the chairman of the board for LumeN XT. This is a private company that is working to improve minimally invasive surgeries by creating a surgical illumination line of products. Beer has been serving in the pharmaceutical, biotech, and diagnostic sectors for more than two and a half decades. He is very happy to be working with the company and commented that he is looking forward to working with the people at LumeN XT who are helping to make surgery much safer. Many surgeons have already benefited from illumination technologies, and the creation of more of these will surely help to move the industry forward. Learn more: http://professionaltales.com/the-voice-of-marc-beer-how-to-be-a-good-leader/

 

Marc Beer was praised by Paul Rhyne, the co-founder of LumeN XT, who commented that he has proven himself by helping many different startups to succeed. He went on to talk about the amount of experience Beer has with helping newer companies as they attempt to become global forces in their industries. Beer has been able to help many companies bring in large amounts of revenue, and Rhyne expects he will be able to do the same for LumeN XT.

 

Marc Beer is known as the chief executive officer and founding chairman of Renovia, Inc. He put the company together in order to help women who suffer from pelvic floor disorders. Before the creation of Renovia, he worked with Minerva Neurosciences Inc. as its founding chairman. This company was created to develop a spread of products that help to treat central nervous system diseases. Minerva continues to work on the development of therapies that can help people who suffer with Parkinson’s Disease, schizophrenia, and other depressive and mood conditions.

 

Before serving with Minerva, Marc Beer worked in many different executive roles where he helped to launch a variety of therapies. He mainly worked with companies and ventures that were in business to create therapies that targeted rare diseases. He worked with Good Start Genetics Inc. as its founding chairman of the board and also served ViaCell as its chief executive officer. In the past, he has also worked with the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board and served Abbott Laboratories as a marketer.